News

Deal Announcements

NeurAxon Nets Strategic Investment

Monday, January 5, 2015 5:31:00 AM PDT | VentureDeal
   Mississauga, Canada  --  Pharmaceutical technology company NeurAxon has landed $1.75 million in new strategic venture capital funding.

NeurAxon is developing "next-generation pain therapeutics focused on the inhibition of neuronal nitric oxide synthase."

Knight Therapeutics made the investment.

The company did not say how the funding proceeds would be used.

NeurAxon is backed by a large syndicate of life science venture capital investors.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1